IP Library Granted Patent US 8,574,659
Granted Patent B2
US 8,574,659 · App. 12/688,132 · Granted Nov 5, 2013

Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,574,659
App. No.
12/688,132
Granted
Nov 5, 2013
Kind
B2
Abstract

A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.

Claims (9)

1. A method of manufacturing a sustained drug delivery system, comprising

positioning a drug core in an impermeable tube, said drug core containing a therapeutically effective amount of an active agent, wherein said impermeable tube is dimensionally stable and capable of supporting its own weight;

cross-sectionally cutting the tube into sections; and

forming a permeable outer layer around at least a portion of a section.

2. The method according to claim 1 , wherein the outer layer is formed by dipping, dropping, spraying, or brushing the section with a solution of polymer.

3. The method according to claim 1 , further comprising positioning an end member to said tube to form a closed-end tube, said end member selected from an impermeable cap and a permeable plug.

4. A method in accordance with claim 3 , wherein positioning an end member comprises joining said end member to a length of said tube to form a vessel-shaped member.

5. A method in accordance with claim 4 , wherein said joining comprises coupling an impermeable cap to said length of tube.

6. The method of claim 1 , wherein the active agent is fluocinolone acetonide.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2022
From: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
To: EYEPOINT PHARMACEUTICALS, INC.; EYEPOINT PHARMACEUTICALS US, INC.; ICON BIOSCIENCE, INC.
Reel/Frame 059365/0112 →
CHANGE OF NAME Recorded Apr 2, 2019
From: PSIVIDA US, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 049108/0700 →
SECURITY INTEREST Recorded Feb 13, 2019
From: EYEPOINT PHARMACEUTICALS, INC.; EYEPOINT PHARMACEUTICALS US, INC.; ICON BIOSCIENCE, INC.
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 048329/0045 →
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2019
From: SWK FUNDING LLC, AS AGENT
To: PSIVIDA CORP.; PSIVIDA US, INC.; ICON BIOSCIENCE, INC.
Reel/Frame 048329/0136 →
SECURITY INTEREST Recorded Apr 5, 2018
From: PSIVIDA CORP.
To: SWK FUNDING LLC, AS AGENT
Reel/Frame 045848/0670 →
CHANGE OF NAME Recorded Jun 27, 2012
From: PSIVIDA INC.
To: PSIVIDA US, INC.
Reel/Frame 028450/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2010
From: GUO, HONG; ASHTON, PAUL
To: CONTROL DELIVERY SYSTEMS, INC.
Reel/Frame 023849/0399 →
MERGER Recorded Jan 26, 2010
From: CONTROL DELIVERY SYSTEMS, INC.
To: PSIVIDA INC.
Reel/Frame 023849/0476 →